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Abstract
Purpose The purpose of this study was to demonstrate the
high number of kidney stones in primary hyperparathyroidism
(PHPT) and the low number of in fact “asymptomatic”
patients.
Methods Forty patients with PHPT (28 female, 12 male; me-
dian age 58 (range 33–80) years; interquartile range 17 years
[51–68]) without known symptoms of kidney stones prospec-
tively underwent multidetector computed tomography
(MDCT) and ultrasound (US) examinations of the urinary
tract prior to parathyroid surgery. Images were evaluated for
the presence and absence of stones, as well as for the number
of stones and sizes in the long axis. The MDCT and US ex-
aminations were interpreted by two experienced radiologists
who were blinded to all clinical and biochemical data.
Statistical analysis was performed using the Wilcoxon
signed-rank test.
Results US revealed a total of 4 kidney stones in 4 (10 %) of
40 patients (median size 6.5 mm, interquartile range
11.5 mm). MDCT showed a total of 41 stones (median size
was 3 mm, interquartile range 2.25 mm) in 15 (38 %) of 40
patients. The number of kidney stones detected with MDCT
was significantly higher compared to US (p = 0.00124).
Conclusions MDCT is a highly sensitive method for the de-
tection of “silent” kidney stones in patients with PHPT. By
widely applying this method, the number of asymptomatic
courses of PHPTmay be substantially reduced.MDCTshould
be used primarily to detect kidney stones in PHPT and to
exclude asymptomatic PHPT.
Keywords Asymptomatic hyperparathyroidism . Kidney
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Introduction
Asymptomatic primary hyperparathyroidism (PHPT) is de-
fined as biochemically verified PHPT that lacks specific
symptoms or signs traditionally associated with hypercalce-
mia or parathyroid hormone excess [1]. Therefore, patients
with PHPT and kidney stone disease are symptomatic by def-
inition. Those patients are at a 15 to 30 % higher risk to
develop kidney stones than the general population, in which
an incidence of 1 % is described [2–6]. A valid detection tool
for kidney stones is crucial at the initial diagnosis of PHPT—
especially in patients with mildly elevated laboratory findings
[7, 8]—and in the course of follow-up to detect patients with
symptomatic disease. The only cure then is parathyroidecto-
mywith a restoration of normocalcemia which, in the majority
of patients, results in a resolution of organic manifestation [9].
Nevertheless, postoperative persistent and recurrent stone dis-
ease has been reported in up to 17 % in long-term follow-up
[2, 9–11]. Calculi burden and new stone formation is impor-
tant in the clinical evaluation of patients with kidney stone
disease in PHPT [12]. Thus, the most sensitive method for
evaluation of kidney stones has to be used to reveal persistent
or recurrent (newly formed) kidney stones after successful
parathyroid surgery [13–15].
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The current guidelines on diagnosis and treatment of
asymptomatic PHPT [1] recommend evaluation of kidney
stone disease and nephrocalcinosis with either abdominal x-
ray, ultrasound or computed tomography as equivalent modal-
ities to differentiate between the asymptomatic and the classi-
cally symptomatic variant. Ultrasound (US) is continuously
performed in the search of kidney stones despite such limiting
factors as overlying bowel gas [16]. Non-enhanced helical
computed tomography (CT) is a widespread and established
method in the detection of kidney stones in patients with acute
flank pain [16–18]. With an increase in the use of CT intrave-
nous pyelography, US is currently playing a secondary role in
the evaluation of kidney stones [19].
We hypothesize that, in patients with PHPT CT may
be more accurate in the detection of kidney stones than
US [16]. The aim of the present study was to compare
the value of US and CT in detecting silent kidney
stones, to identify patients with symptomatic PHPT, to
improve the postoperative follow-up of stone carriers




In this prospective study, 40 patients (28 female, 12male) with
biochemically proven PHPT were consecutively evaluated
over a 1-year period (see Table 1).
According to Hesch [20], all patients were classified
“asymptomatic” clinically. The patients were neither “mini-
mally symptomatic” (showing arterial hypertension,
osteopenia/osteoporosis, hypercalcemic symptoms) nor
“symptomatic” (osseous or gastrointestinal manifestation).
Particularly, the study patients had no kidney stone disease,
nephrocalcinosis, or impaired renal function.
No patient had a pharmacological anamnesis regarding
nephrotoxic or lithogenic agents.
Diagnosis of PHPTwas based on common laboratory tests
[21]. The median age was 58 years (range 33 to 80, interquar-
tile range 17 years [51 to 68]).
Four (10 %) of the 40 patients had a history of kidney
stones, two of whom underwent surgical extraction. In the
remaining two subjects, the stones passed spontaneously.
However, at the time of diagnosis of PHPT (including the
preceding 5 years at least) none of those patients was afflicted
with kidney stones.
Imaging studies
US and CT were performed 12 to 48 h prior to parathyroid
surgery.
US of the kidneys was performed by a highly experienced
radiologist and with a high-end machine (ATL, HDI 5000,
Seattle, USA) using a 5 or a 7-MHz curved array transducer.
Documentation included multiple anatomic planes, and at
least three images in the longitudinal and three in the trans-
verse section, respectively [16].
Multidetector CT (MDCT; Volume zoom, Siemens,
Forchheim, GER) of the abdomen was performed with pa-
tients in a prone position. The scanning protocol consisted of
80 kV and 100 mAs low-dose scanning using a 4 × 1 mm
collimation, 6-mm table feed, 0.5-s rotation time.
Reconstruction was obtained in the axial and coronal plane
with 1.5-mm slice thickness. No intravenous or oral contrast
agent was administered.
Imaging analysis
The obtained US images were evaluated for the presence and
absence of stones, as well as for the number of stones and sizes
in the long axis. The stones were defined as hyperechogenicities
with dorsal shadowing [16].
Table 1 Laboratory findings (mean ± standard deviation) and demographic data (median age)
sCa iPTH 25-OH VitD 1, 25-OH VitD Crea P 24 h uCa n Age Female Male
Normal range 2.1–2.6 15–65 > 75 25–86.5 0.5–1.3 0.8–1.6 2.5–7 .5
Unit mmol/l pg/ml nmol/l pg/ml mg/dl mmol/l mmol/24 h
Total 2.783 ± 0.22 191 ± 165 42 ± 30 56 ± 26 0.97 ± 0.23 0.74 ± 0.19 7.9 ± 4.7 40 58 28 12
US positive 2.69 ± 0.14 94 ± 18 43 ± 25 36 ± 13 0.90 ± 0.11 0.69 ± 0.14 7.1 ± 3.4 4 55 3 1
US negative 2.85 ± 0.22 202 ± 170 42 ± 31 59 ± 26 0.97 ± 0.24 0.74 ± 0.19 8.1 ± 5.1 36 60 25 11
MDCT postitive 2.83 ± 0.22 243 ± 215 47 ± 43 50 ± 26 1.01 ± 0.29 0.72 ± 0.12 7.6 ± 2.9 15 56 10 5
MDCT negative 2.83 ± 0.22 160 ± 120 39 ± 19 60 ± 25 0.94 ± 0.18 0.75 ± 0.22 8.2 ± 6.4 25 60 18 7
sCa serum calcium; albumine corrected; chemical autoanalyzer (Olympus, Hamburg, Germany), iPTH intact parathyroid hormone (Elecsys 1010
Autoanalyzer (Roche, Mannheim, Germany), 25-(OH)D3 25-hydroxycholecalciferol; chemiluminescence immunoassay BLiaison – 25OH-VitD-
Totalassay^ (DiaSorin, Italy) or Elecsys B25OH- assay^ on COBAS E411 (Roche, Mannheim, Germany), 1,25-(OH)D3 1,25-dihydroxycholecalciferol;
analyzed manually via chromatography and radioimmunosorbent assay (DiaSorin, Italy), Crea serum creatinine, P serum phosphate, 24 h uCa 24-h
urinary calcium excretion
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MDCT examinations were evaluated on the screen of a
PACS System, again for the absence and presence of stones,
as well as for the number of stones and sizes in the long axis.
The stones were defined as high-attenuating opacities [16].
Two experienced radiologists evaluated the MDCTand US
examinations as a team and provided interpretations in unison.
Both investigators were blinded to all clinical and biochemical
data. In order to prevent bias, MDCT was assessed 1 week
after the evaluation of US. The location of each stone was
recorded as being in either the right or the left kidney.
In two patients, multiple (uncountable) stones and paren-
chymal calcifications were found. For size measurements, ten
stones of each of those two patients were evaluated which
were easily measurable.
Statistical analysis
Analysis was performed using a statistical software package
(SPSS 11, SPSS Inc., Chicago, USA). Comparison of the
number of detected stones withMDCTand USwas performed
with the Wilcoxon signed-rank test. Statistical significance
was set at a p value of 0.05.
Surgery was performed on all patients and a single para-
thyroid adenoma was verified histopathologically. By defini-
tion, all patients were cured. Cure was documented by
normocalcemia 5 years after surgery.
Results
Ultrasound
In 4 (10 %) of 40 patients, a total of four kidney stones could
be detected. The median size was 6.5 mm, quartiles ranging
from 2.25 to 13.75 mm (interquartile range 11.5 mm). Three
females and one male were affected. In three cases, the stones
were located in the left, in one case in the right kidney.
Multidetector computed tomography
MDCT identified a total of 41 stones in 15 (38 %) of 40
patients. The size of the stones ranged from 2 to 15 mm with
a median size of 3 mm (interquartile range 2.25 mm [2.5–
4.75 mm]). Kidney stone formation affected ten females and
five males. In 8 (53 %) patients, stones were revealed in both
kidneys, in 2 (13 %) in the left and in 5 (33 %) in the right
kidney only.
Ultrasound vs multidetector computed tomography
The number of detected stones was significantly higher with
MDCT than with US (41 vs 4, p = 0.00124).
In one patient, a kidney stone was suspected with US, but
this stone failed to be detected withMDCT. In two subjects, in
whom numerous calculi were seen with MDCT, only one was
found to have a kidney stone with US, measuring 15 mm in
diameter. The remaining calcifications in both kidneys were
not seen with US (Table 2).
Discussion
None of the patients had clinical signs of kidney stones upon
diagnosis of PHPT or other organ manifestations of classical
PHPT [22] and were by definit ion [1] cl inically
“asymptomatic.”
Following the current recommendations [23], all patients
with biochemically proven PHPT who have no contraindica-
tions for a surgical intervention were presented in a multidis-
ciplinary endocrine conference. The risks, benefits, and poten-
tial complications of surgery were discussed with the patients
and all decided surgery as the treatment of choice.
In this study protocol, MDCT proved significantly superior
to US in the detection rate of clinically “silent” kidney stones
in patients with initially “asymptomatic” PHPT.
As shown in this study, a number of patients clinically
classified “asymptomatic” may have “silent” organ manifes-
tations and therefore be in fact “symptomatic.” In many ways,
“symptomatic” patients profit from surgery [2, 9]. In the cur-
rent guidelines [1], “asymptomatic” patients compose a pa-
tients’ group inheriting only a “relative indication” for surgery
while in “symptomatic” patients early surgical intervention is
recommended [23], so those patient groups need to be dis-
criminated [24].
Therefore, the current guidelines aim to enhance the
screening for oblique organ manifestations by recommending
renal examinations by ultrasound, the proportion of patients
identified with kidney stones might be smaller if ultrasound is
used compared toMDCTand consequently, hidden symptoms
might be missed. Another study concluded recently [25], that
through the use of aforementioned guidelines more surgical




n % n % n %
MDCT Positive 3 7.5 12 30.0 15 37.5
Negative 1 4.0 24 60.0 25 62.5
Total 4 10.0 36 90.0 40 100.0
n = patients; 40 patients were evaluated prospectively
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candidates are identified. Nevertheless, some patients might
persist who do not meet criteria for surgery if only screened
with US. We assume that screening for kidney stones by
MDCT could direct more patients from this uncertain group
towards surgical treatment. Due to the significantly higher
number of stone carriers, centers not able or unwilling to per-
formMDCT to definitively rule out renal involvement should
apply a low threshold regarding symptomatology to indicate
surgery early because of possibly overlooked kidney stones
when applying US only.
The superiority of MDCT in determining the size, number,
and the position of kidney stones was convincing in this study,
and the possibility of low-dose protocols seems to justify the
use of ionizing radiation. As shown, there was a larger number
of patients with clinically “silent” kidney stones detected by
MDCTcompared to US [6, 16], demonstrating the superiority
of MDCT and the necessity of an adaption of the current
consensus [1].
The performance of MDCT was related to the excellent
contrast resolution and discrimination of different attenuation
within the kidneys. The lack of acoustic shadowing that may
occur with intervening tissue of different acoustic impedance
can lead to a miss of stones with US [26]. This could also be
the reason for the US diagnosis of kidney stones in one patient
that could not be confirmed with MDCT.
MDCT captures a volume that includes the entire kidney,
allowing a complete evaluation of the organ. With US, due to
potentially overlying bowel gas and patients’ varying body
habitus, some areas of the kidney may be hidden [16].
Furthermore, MDCT is less operator-dependent than US
which requires skillful radiological expertise [16].
As reported previously, the size of stones seems to influ-
ence the detection rate with US. Thus, the median size of
stones was 6.5 mm as found with US and 3 mm as detected
with MDCT [26]. Most stones missed with US were smaller
than 5 mm. Kidney stones with a size of less than 5 mm may
pass spontaneously, indicating the limited value of US in
follow-up and identification of small stones in known stone
formers [16] as well as in distinguishing recurrent from per-
sistent silent kidney stones.
Preoperative radiological assessment is crucial to deter-
mine the directions of further postoperative follow-up in pa-
tients with “silent” kidney stones [2, 10, 13, 22].
The study documents that MDCT is more sensitive to de-
tect kidney stones than ultrasound.
Conclusion
Based on low-dose protocols and therefore a lower x-ray ex-
posure, we propose to consider MDCT with its broad avail-
ability as the “gold standard” imaging technique for detecting
kidney stones in patients with PHPT to identify silent stone
carriers in need of surgical treatment, as by this approach
patients can be cured who would otherwise develop stones
during follow-up [27]. By applying this technique, the very
scarce group of patients with “asymptomatic” PHPT may be
further diminished. The current guidelines on the management
of asymptomatic PHPT [1] should be adapted to this finding.
If not used primarily, MDCTshould particularly be considered
in patients in the border zone of indication for surgery.
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